Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Drug Metab Dispos ; 32(4): 447-54, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15039299

RESUMO

Oxycodone undergoes N-demethylation to noroxycodone and O-demethylation to oxymorphone. The cytochrome P450 (P450) isoforms capable of mediating the oxidation of oxycodone to oxymorphone and noroxycodone were identified using a panel of recombinant human P450s. CYP3A4 and CYP3A5 displayed the highest activity for oxycodone N-demethylation; intrinsic clearance for CYP3A5 was slightly higher than that for CYP3A4. CYP2D6 had the highest activity for O-demethylation. Multienzyme, Michaelis-Menten kinetics were observed for both oxidative reactions in microsomes prepared from five human livers. Inhibition with ketoconazole showed that CYP3A is the high affinity enzyme for oxycodone N-demethylation; ketoconazole inhibited >90% of noroxycodone formation at low substrate concentrations. CYP3A-mediated noroxycodone formation exhibited a mean K(m) of 600 +/- 119 microM and a V(max) that ranged from 716 to 14523 pmol/mg/min. Contribution from the low affinity enzyme(s) did not exceed 8% of total intrinsic clearance for N-demethylation. Quinidine inhibition showed that CYP2D6 is the high affinity enzyme for O-demethylation with a mean K(m) of 130 +/- 33 microM and a V(max) that ranged from 89 to 356 pmol/mg/min. Activity of the low affinity enzyme(s) accounted for 10 to 26% of total intrinsic clearance for O-demethylation. On average, the total intrinsic clearance for noroxycodone formation was 8 times greater than that for oxymorphone formation across the five liver microsomal preparations (10.5 microl/min/mg versus 1.5 microl/min/mg). Experiments with human intestinal mucosal microsomes indicated lower N-demethylation activity (20-50%) compared with liver microsomes and negligible O-demethylation activity, which predict a minimal contribution of intestinal mucosa in the first-pass oxidative metabolism of oxycodone.


Assuntos
Hidrocarboneto de Aril Hidroxilases/metabolismo , Citocromo P-450 CYP2D6/metabolismo , Intestinos/ultraestrutura , Microssomos Hepáticos/metabolismo , Oxirredutases N-Desmetilantes/metabolismo , Oxicodona/metabolismo , Hidrocarboneto de Aril Hidroxilases/genética , Hidrocarboneto de Aril Hidroxilases/farmacologia , Biotransformação , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP2D6/farmacologia , Citocromo P-450 CYP3A , Sistema Enzimático do Citocromo P-450/genética , Sistema Enzimático do Citocromo P-450/metabolismo , DNA Complementar/genética , Humanos , Mucosa Intestinal/metabolismo , Intestinos/efeitos dos fármacos , Cetoconazol/metabolismo , Cetoconazol/farmacologia , Cinética , Taxa de Depuração Metabólica , Metilação/efeitos dos fármacos , Microssomos/efeitos dos fármacos , Microssomos/metabolismo , Microssomos Hepáticos/química , Microssomos Hepáticos/efeitos dos fármacos , Estrutura Molecular , Morfinanos/antagonistas & inibidores , Morfinanos/química , Morfinanos/metabolismo , Oxirredutases N-Desmetilantes/genética , Oxirredutases N-Desmetilantes/farmacologia , Oxicodona/farmacologia , Oximorfona/química , Oximorfona/metabolismo , Ligação Proteica/efeitos dos fármacos , Quinidina/efeitos adversos , Quinidina/antagonistas & inibidores , Quinidina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA